A group of disgruntled Mylan investors launched a campaign late Tuesday to block the re-election of six directors over their exorbitant—and increasing—compensation. That’s according to a report in the Wall Street Journal.

In a letter sent to fellow shareholders, the group lambasted hefty bonuses and salary increases that came as the company faced backlash for the skyrocketing price of its life-saving EpiPen devices. Such outrage is likely to continue given that a new government report released today suggests that Mylan overcharged taxpayers $1.27 billion dollars for EpiPens over 10 years.

The ongoing EpiPen pricing scandal has caused Mylan "significant reputational and financial harm ," the investors complained. Yet directors continued to be rewarded. The investors were particularly critical of Chairman Robert Coury, who received more than $160 million in compensation in 2016 and will receive a $1.8 million per year “cash retainer” as part of a deal made with Mylan last year. Trade publication FiercePharma reports that Coury is the highest-paid executive in the drug industry.

“Mylan’s board reached new lows in corporate stewardship in 2016 when it agreed to make extraordinary and egregious payments in 2016 and over the next five years,” the investors wrote in the letter.

That letter is signed by four institutional investors: New York City and New York State pension funds, the California State Teachers’ Retirement System, and Dutch pension fund PGGM. Together, they own about 4.3 million shares of Mylan, which represents less than one percent of its outstanding shares, the Wall Street Journal reports. As such, the group’s protest is more of a high-profile flap than a real threat to the six directors, who are all running unopposed.

But frustration has been mounting among investors over Mylan’s greedy ways. Last year, more than a third of investors voted against the company’s compensation plans. And the EpiPen scandal has hit share prices. Although they’re up four-fold since 2002, share prices have fallen by 10 percent in the past 12 months, the AP notes.

Things might get worse: today, the Office of the Inspector General for the Department of Health and Human Services released an analysis (PDF) that estimated how much Mylan overcharged taxpayers for its EpiPens. By misclassifying the devices, the company stiffed the Medicaid rebate program by as much as $1.27 billion between 2006 and 2016, the report concludes. In October, Mylan reportedly agreed to pay just $465 million to settle the issue with the government.